5 Signals Reshaping 2026 Access Planning
Market access planning is entering a new cycle. Pricing pressure, biosimilar competition, formulary narrowing, pull-through friction, and rare disease dynamics are changing how pharmaceutical and biotech teams need to prepare for 2026 and beyond.
In eMAX Health Systems’ webinar, The Access Inflection: When the 2025 Playbook Stops Working, a live panel of senior payer and market access leaders discussed five real-time signals that may reshape launch planning, evidence development, contracting strategy, and stakeholder engagement.
This insight series breaks down each signal and what manufacturers should be pressure-testing now.
Explore the 5 Signals
Each signal includes a full insight article with payer perspective, planning questions,
and implications for 2026 access strategy.
1. Pricing in the Post-MFN World
Pricing strategy now depends more heavily on payer evidence expectations, contracting tolerance, and current market dynamics.
2. The Biosimilar Cliff Cascade
LOE is no longer just a product event. Biosimilar and generic entry can quickly reset class economics and access expectations.
3. The Quiet Formulary Crackdown
Payers are tightening access through narrower coverage, utilization management, and greater scrutiny of products that lack clear differentiation.
Full insight coming soon →
4. The Pull-Through Trap
Approval alone is not enough. Operational friction, reimbursement complexity, and provider workflow barriers can slow real-world uptake.
Full insight coming soon →
5. Rare Disease as a Leading Indicator
Rare disease markets often show where access strategy is headed next, especially around evidence, value, and stakeholder expectations
Full insight coming soon →
Turn Current Payer Insight Into Access Strategy
The signals in this series are moving quickly. MAVA® helps pharmaceutical and biotech teams bring timely payer and healthcare decision-maker insight into high-stakes planning decisions before market conditions shift.
With rapid, confidential engagement from curated stakeholder panels, MAVA helps Commercial, Medical, HEOR, Pricing, and Access teams pressure-test assumptions around pricing, evidence, contracting, formulary strategy, and pull-through planning.
Watch the Webinar Replay & Download the signal briefs
Hear the full discussion from senior payer and market access leaders in The Access Inflection: When the 2025 Playbook Stops Working.
The panel explored the five signals reshaping access strategy and what pharmaceutical and biotech teams should be thinking about now as they prepare for 2026 and beyond.
